buyModerate cluster of 3
Linda Palczuk bought $40k of AVDL
director at AVADEL PHARMACEUTICALS PLC. 5,000 shares at an average of $7.93, traded Jan 21, 2025, filed Jan 22, 2025.
Conviction score
44Value
$40k
5,000 shares
Holdings after
67,900
+8% from before
From 52-week low
-
no price yet
From 52-week high
-
no price yet
Score components
- +15RoleDirector
- +6Trade size$40k at market
- +3Relative to holdingsHoldings up 8%
- 0Price contextNo price history yet
- +15Cluster3 insiders buying within 14 days
- +5Repeat buying2 buys in 90 days
- 0Track recordToo few past buys to judge (0 with prices)
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Rows in this filing
Every transaction in Form 4 0001104659-25-005248, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Jan 21, 2025 | POpen-market purchase Ordinary Shares | +5,000 | $7.93 | $40k | 67,900 | Jan 22, 2025 |
Related signals
Other insiders at AVADEL PHARMACEUTICALS PLC and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 53Moderate | AVDLsell AVADEL PHARMACEUTICALS PLC | Weiss Asset Management LP other | $233M 11,112,052 shares | -100% | |
| 46Moderate | AVADEL PHARMACEUTICALS PLC | Eric J Ende director | $235k 30,000 shares | +17% | |
| 42Moderate | AVADEL PHARMACEUTICALS PLC | Peter J. Thornton director | $80k 10,000 shares | +11% | |
| 42Moderate | AVADEL PHARMACEUTICALS PLC | Thomas S McHugh Chief Financial Officer | $24k 2,300 shares | +3% | |
| 47Moderate | AVADEL PHARMACEUTICALS PLC | Thomas S McHugh Chief Financial Officer | $52k 5,000 shares | +6% | |
| 35Weak | AVADEL PHARMACEUTICALS PLC | Linda Palczuk director | $31k 3,000 shares | +5% | |
| 48Moderate | AVADEL PHARMACEUTICALS PLC | Geoffrey Michael Glass director | $200k 20,279 shares | +34% | |
| 58Moderate | AVADEL PHARMACEUTICALS PLC | Gregory J Divis Chief Executive Officer | $100k 10,000 shares | - | |
| 27Weak | AVDLbuy AVADEL PHARMACEUTICALS PLC | Thomas S McHugh Chief Financial Officer | $29k 2,000 shares | +3% | |
| 40Moderate | AVADEL PHARMACEUTICALS PLC | Mark Anthony McCamish director | $1.1M 75,000 shares | -53% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.